Abbvie Inc.

Stacy A Van Epps

Kristine E Frank

Michael M Friedman

Lu Wang

J Martin Herold

Marlon D Cowart

Anil Vasudevan

Michael R Schrimpf

George S Sheppard

Huaqing Liu

Marc J Scanio

Michael Z Hoemann

Maria A Argiriadi

Eric C Breinlinger

Noel S Wilson

Augustine Osuma

Xiangdong Xu

Grier A Wallace

Heather M Davis

Dominique Bonafoux

Zhi Wang

Raymond Huntley

Gagandeep K Somal

Jennifer Van Camp

Thomas R Vargo

Wei Qiu

Andrew J Little

David J Hardee

Ellen Yulin Tsai Chien

Matthew P Webster

Disclosed herein are compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein R, R2, R, R, R, X, X, X, X, X, nad n are as defined herein, pharmaeceutical compositions 2C X, and n are as defined herein, pharmaceutical compositions comprising same, and methods of preparation and use. 

Inhibitors of tyrosine kinase 2 mediated signaling

The invention provides compounds of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.

Primary carboxamides as BTK inhibitors

Growing community of inventors

Ashland, MA, United States of America

Stacy A Van Epps